Biotech Startup Creation
Company-building experience informs team development, operating priorities, and the translation of scientific opportunity into a focused development program.
About perSeptive Diagnostics
Bringing Diagnostic Science and Company-Building Experience Together
perSeptive Diagnostics brings together diagnostic science, biotech startup experience, business development, and financial expertise to advance our lead iNOS host-response diagnostic for earlier sepsis detection.
Experience
Diagnostic Experience From Discovery to Commercialization
Our board and leadership team bring together more than sixty years of combined experience developing in vitro diagnostics—from biomarker discovery and immunoassay development through biosensor engineering, analytical validation, manufacturing, quality systems, and commercialization.
Beyond the Science
Experience to Build the Company and Prepare for Market
Our founding team, board, and leadership combine diagnostic expertise with experience in biotech startup creation, business and corporate development, finance, and commercialization. These capabilities shape how we advance the iNOS lead program.
Business & Corporate Development
Business development experience supports partnership strategy and the evaluation of clinical, technology, and commercial collaborations that could advance the lead diagnostic.
Finance & Capital Planning
Financial expertise informs budgeting, capital planning, and resource allocation, connecting investment priorities to development milestones and the needs of a growing diagnostic business.
Diagnostic Commercialization
Experience across diagnostic development, manufacturing, quality systems, and commercialization helps connect product design with laboratory workflows, customer needs, and preparation for market entry.
Our Approach
A Focused Approach to Building a Diagnostic Business
Our development decisions connect biological relevance and analytical evidence with clinical needs, operational readiness, and a practical path to market.
Biology First
Meaningful diagnostic innovation begins with the biology driving disease rather than only its later clinical consequences.
Evidence Driven
Development is guided by scientific evidence, rigorous assay design, quantitative measurement, and analytical validation.
Focused Execution
We prioritize the iNOS sepsis diagnostic, aligning development milestones, resources, and commercial planning around the lead program.
What We Are Building
Advancing the iNOS Sepsis Diagnostic Toward Clinical Use
Our lead program is a quantitative blood-based diagnostic for vesicle-associated inducible nitric oxide synthase (iNOS), being developed to support earlier sepsis recognition alongside existing clinical assessment and testing.
Our technical experience spans biomarker science, immunoassay development, biosensor engineering, and microfluidics. We bring this expertise together with manufacturing, quality-system, and commercialization experience to guide diagnostic development.
Our path forward centers on assay reliability, clinical evidence, and a focused market-entry strategy. Additional biomarkers and broader applications remain future opportunities. Explore the development and market-entry roadmap.
Our Purpose
More Information When Sepsis Decisions Matter
Our goal is to provide clinicians with additional host-response information that may support earlier sepsis recognition. Establishing its clinical value and fit within existing care is central to the development program.
Research and Development
perSeptive Diagnostics is an early-stage biotechnology company advancing proprietary host-response diagnostic technologies. Our platform is currently under development and has not been cleared or approved for clinical use.